Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.56 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020779 | 0.85 | LRRK2 (0.53) | LRRK2FGFR1FGFR2FGFR3TTK | |
| SCHEMBL15021622 | 0.81 | LRRK2 (0.55) | LRRK2 | |
| SCHEMBL15020972 | 0.81 | LRRK2 (0.56) | LRRK2 | |
| SCHEMBL15020989 | 0.81 | LRRK2 (0.56) | LRRK2 | |
| SCHEMBL15020986 | 0.80 | HSP90AA1 (0.38) | LRRK2PGK1 | |
| SCHEMBL15020772 | 0.80 | LRRK2 (0.56) | LRRK2 | |
| SCHEMBL15020969 | 0.79 | LRRK2 (0.56) | LRRK2FGFR1FGFR2FGFR3 | |
| SCHEMBL15021047 | 0.77 | LRRK2 (0.54) | LRRK2 | |
| SCHEMBL15020781 | 0.77 | LRRK2 (0.54) | LRRK2 | |
| SCHEMBL15021111 | 0.76 | LRRK2 (0.38) | LRRK2PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791130-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-07-29 | — | — | US | claimed |
| US-8791130-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130158057-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158057-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, P2RX6 | LRRK2 1/4885PGK1 1430/4885FGFR1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.